

Arkusz Kuryk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8084904/publications.pdf>

Version: 2024-02-01

53
papers

1,230
citations

430874

18
h-index

395702

33
g-index

58
all docs

58
docs citations

58
times ranked

1682
citing authors

#	ARTICLE	IF	CITATIONS
1	Innate Immunity to Adenovirus. <i>Human Gene Therapy</i> , 2014, 25, 265-284.	2.7	185
2	Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. <i>Journal of Controlled Release</i> , 2018, 283, 223-234.	9.9	95
3	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. <i>Journal of Controlled Release</i> , 2019, 294, 165-175.	9.9	93
4	Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. <i>Oncolmmunology</i> , 2019, 8, e1532763.	4.6	80
5	Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies. <i>Viruses</i> , 2018, 10, 558.	3.3	73
6	Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. <i>Oncolmmunology</i> , 2016, 5, e1105429.	4.6	70
7	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. <i>Cancers</i> , 2020, 12, 3057.	3.7	50
8	Heterologous and cross-species tropism of cancer-derived extracellular vesicles. <i>Theranostics</i> , 2019, 9, 5681-5693.	10.0	48
9	Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-Δ24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. <i>International Journal of Cancer</i> , 2016, 139, 1883-1893.	5.1	46
10	Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 651-660.	4.1	41
11	Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. <i>Journal of Medical Virology</i> , 2019, 91, 1702-1706.	5.0	37
12	Antitumor-specific T cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-Δ24-GM-CSF) in peritoneal mesothelioma mouse model. <i>Journal of Medical Virology</i> , 2018, 90, 1669-1673.	5.0	36
13	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment. <i>PLoS ONE</i> , 2017, 12, e0182715.	2.5	34
14	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16002.	4.4	32
15	Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. <i>Journal of Medical Virology</i> , 2020, 92, 1309-1315.	5.0	26
16	A novel <i>in silico</i> framework to improve MHC-I epitopes and break the tolerance to melanoma. <i>Oncolmmunology</i> , 2017, 6, e1319028.	4.6	25
17	2020 ASGCT Annual Meeting Abstracts. <i>Molecular Therapy</i> , 2020, 28, 1-592.	8.2	24
18	Environmental Surveillance of Non-polio Enteroviruses in Poland, 2011. <i>Food and Environmental Virology</i> , 2015, 7, 224-231.	3.4	20

#	ARTICLE	IF	CITATIONS
19	Genetic analysis of poliovirus strains isolated from sewage in Poland. <i>Journal of Medical Virology</i> , 2014, 86, 1243-1248.	5.0	18
20	Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells. <i>Pharmaceutics</i> , 2021, 13, 949.	4.5	18
21	The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2249.	4.1	17
22	Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. <i>Cancer Gene Therapy</i> , 2019, 26, 26-31.	4.6	16
23	Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. <i>International Journal of Molecular Sciences</i> , 2019, 20, 621.	4.1	16
24	Sulfone derivatives enter the cytoplasm of <i>Candida albicans</i> sessile cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 191, 112139.	5.5	15
25	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. <i>Nanotheranostics</i> , 2021, 5, 1-7.	5.2	13
26	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2. <i>Vaccines</i> , 2020, 8, 293.	4.4	12
27	Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	11
28	Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. <i>Pharmaceutics</i> , 2021, 13, 547.	4.5	10
29	In Vitro Anti-Candida Activity and Action Mode of Benzoxazole Derivatives. <i>Molecules</i> , 2021, 26, 5008.	3.8	9
30	Tetrazole derivatives bearing benzodiazepine moiety synthesis and action mode against virulence of <i>Candida albicans</i> . <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114060.	5.5	4
31	661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model. <i>Molecular Therapy</i> , 2016, 24, S262.	8.2	3
32	ESGCT 27th Annual Congress In collaboration with SETGyc Barcelona, Spain October 22-25, 2019 Abstracts. <i>Human Gene Therapy</i> , 2019, 30, A1-A221.	2.7	3
33	The Antifungal Action Mode of N-Phenacyldibromobenzimidazoles. <i>Molecules</i> , 2021, 26, 5463.	3.8	3
34	The Detection of Enteroviruses in Sewage Using Caco-2 Cells. <i>Polish Journal of Microbiology</i> , 2013, 62, 97-100.	1.7	3
35	Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform. , 2015, 3, .		2
36	Antifungal polybrominated proxiphylline derivative induces <i>Candida albicans</i> calcineurin stress response in <i>Galleria mellonella</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127545.	2.2	2

#	ARTICLE	IF	CITATIONS
37	361â€¦A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma â€” 12 month analysis of biomarkers and clinical outcomes. , 2020, , .		2
38	71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice. Molecular Therapy, 2015, 23, S31.	8.2	1
39	408. Oncolytic Vaccines in Combination with PD-L1 Blockade for the Treatment of Melanoma. Molecular Therapy, 2016, 24, S161-S162.	8.2	1
40	1083P A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma. Annals of Oncology, 2021, 32, S897-S898.	1.2	1
41	Abstract A034: Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma. , 2016, , .		1
42	220. Evaluation of the Efficacy of a New Oncolytic Vaccine Platform in Humanized Mice. Molecular Therapy, 2015, 23, S86-S87.	8.2	0
43	622. Oncolytic Adenoviruses Loaded With Active Drugs as a Novel Drug Delivery System for Cancer Therapy. Molecular Therapy, 2015, 23, S247.	8.2	0
44	665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102. Molecular Therapy, 2015, 23, S264-S265.	8.2	0
45	659. Oncolytic Adenovirus Loaded with Bioactive Modified Peptide as a Novel Approach to Treat Cancer. Molecular Therapy, 2016, 24, S261.	8.2	0
46	642. Oncolytic Vaccines with Modified Tumor Epitopes for Cancer Immunotherapy. Molecular Therapy, 2016, 24, S254.	8.2	0
47	Enhanced anti-cancer vaccines with a new epitope improvement system. Annals of Oncology, 2016, 27, viii2.	1.2	0
48	Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01). Annals of Oncology, 2019, 30, xi7-xi8.	1.2	0
49	ESGCT 2021: Virtually Pan-European. Human Gene Therapy, 2021, 32, 978-978.	2.7	0
50	Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC). , 2019, , .		0
51	Abstract 4562: Next generation Oncos oncolytic adenovirus with novel anti-cancer double-transgenes shows synergistic anticancer effect in melanoma mouse model. , 2020, , .		0
52	462â€¦A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma â€” 24 month survival data. , 2021, 9, A491-A491.		0
53	368â€¦Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors. , 2021, 9, A396-A396.		0